Simmons Jeffrey N., president, CEO and director of Elanco Animal Health (ELAN), has filed 42 Form 4 transactions in the company’s stock, and the pattern is overwhelmingly one-sided. Across all filings, he has recorded $578,338 in open-market purchases and zero open-market sales. The only outright buy in the recent window came on May 15, 2026, when he acquired ELAN shares worth $99,842.54. That transaction stands apart from the steady cadence of compensation-related grants and awards that dominate his filing history.
The bulk of Simmons’s recent activity consists of recurring “A” code grants, each valued at roughly $2,826.93, appearing on a biweekly schedule from January through July 2026. These are compensation awards, not discretionary purchases, and they cluster around standard pay cycles. Larger awards on March 6, 2026, totaled $105,064.39 each, and a series of zero-value grants on March 1, 2026, reflect performance-based or restricted stock issuances. Two “F” code transactions on March 1 and March 3, 2026, show shares withheld to cover tax obligations—$6.07 million and $942,902.24, respectively—which are automatic and not indicative of a selling bias.
The data reveals a CEO who has not sold a single share on the open market, while maintaining a modest but consistent purchase history. The May 15 buy, at nearly $100,000, is the most recent and largest discretionary acquisition, suggesting conviction in ELAN’s valuation at that time. The absence of any “S” or “D” sales, combined with the regular accumulation of grants, points to a net-positive insider position. Simmons’s filings are a textbook case of a long-term holder who lets compensation accrue and occasionally adds to his stake, with no recent indication of profit-taking or distribution.
AI-assisted summary